Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Bright Minds Biosciences Inc. (DRUG)

June 2, 2026 6:57 AM EDT Send to a Friend
H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $145.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login